GC69062
Enavatuzumab
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody that targets the TNF-like weak inducer of apoptosis receptor (TWEAK)· TWEAK (Fn14; TNFRSF12A) is the natural ligand for the TweakR receptor and can stimulate various cellular responses· Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody-dependent cell-mediated cytotoxicity (ADCC)· Enavatuzumab actively recruits and activates bone marrow effector cells to kill tumor cells· In vitro and in vivo, enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts
ChemicalCAS1062149-33-0
- CAS number
- 1062149-33-0
- Molecular weight
- —
- Formula
- —
- Catalogue number
- GC69062
- Brand
- GLPBIO
Ordering in Israel
- Lead time
- Ships from the manufacturer to your lab in 8–14 business days; customs and cold chain handled by LABO Scientific.
- Pricing
- Quoted in ILS, excl. VAT. Add the item to your quote and we confirm the final price, usually the same business day.
- Documents
- Lot certificate of analysis and manufacturer SDS are emailed with your order confirmation.
- Who we serve
- Universities, hospitals and biotech companies across Israel. Research use only — not for diagnostic or therapeutic use.
- Questions
- WhatsApp · +972-55-990-7576 · orders@labo.co.il